



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



AZD0095

Cat. No.:	HY-148517
CAS No.:	2750001-23-9
Molecular Formula:	C ₂₇ H ₃₂ N ₈ O ₂
Molecular Weight:	500.6
Target:	Monocarboxylate Transporter
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 10 mg/mL (19.98 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.9976 mL	9.9880 mL	19.9760 mL
		5 mM		0.3995 mL	1.9976 mL	3.9952 mL
		10 mM		0.1998 mL	0.9988 mL	1.9976 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1 mg/mL (2.00 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (2.00 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (2.00 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	AZD0095 is a selective and orally active MCT4 inhibitor (IC ₅₀ : 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205) ^[1] .
IC ₅₀ & Target	MCT4 1.3 nM (IC ₅₀)
In Vitro	AZD0095 (0-50 μM) inhibits cell proliferation in NCI-H358 cells (high expression of MCT4), with an IC ₅₀ of 26 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AZD0095 (100 mg/kg, p.o. bid) together with [Cediranib](#) (3 mg/kg, p.o.) reduces tumor growth in a murine NCI-H358 xenograft [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine NCI-H358 xenograft ^[1]
Dosage:	100 mg/kg together with Cediranib (3 mg/kg)
Administration:	Oral administration (p.o.)
Result:	Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.

REFERENCES

[1]. Goldberg FW, et al. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. J Med Chem. 2022 Dec 16.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA